CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB2231 : HS-SY-II]

15489 Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T. Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma Cancers (Basel) 2021 13(8):1823 PubMed ID: 33920416 DOI: 10.3390/cancers13081823

16680 Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N. Effect of temozolomide on the viability of musculoskeletal sarcoma cells Oncol Lett 2015 10(4):2511-2518 PubMed ID: 26622881 DOI: 10.3892/ol.2015.3506

16758 Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W. SRC signaling is crucial in the growth of synovial sarcoma cells Cancer Res 2013 73(8):2518-28 PubMed ID: 23580575 DOI: 10.1158/0008-5472.CAN-12-3023

9008 Hill BB, Zweng TN, Maley RH, Charash WE, Toursarkissian B, Kearney PA. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) Cancer Lett 2008 272(2):336-44 PubMed ID: 18760530 DOI: 10.1016/j.canlet.2008.07.021

3904 Ono H, Yoshikawa H, Ueda T, Yamamura H, Kudawara I, Manou M, Ishiguro S, Funai H, Koyanagi Y, Araki N, Hashimoto N, Sonobe H, Tatsuta M, Takahashi K. Expression of smooth muscle calponin in synovial sarcoma Sarcoma 1999 3(2):107-13 PubMed ID: 18521272 DOI: 10.1080/13577149977730

3502 Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y, Mizobuchi H, Yamamoto H, Kumano O, Abe S. Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II Lab Invest. 1992 67:498-505 PubMed ID: 1331610

Top

User's Publication

22901 Yao H, Toyoda H, Takada N, Oebisu N, Orita K, Ban Y, Saito K, Nakazawa K, Kobayashi Y, Taniwaki H, Ohira C, Oh JS, Shirafuji T, Terai H, Nakamura H. Anti-Tumor Effect of Non-Thermal Atmospheric Pressure Plasma-Activated Medium on Synovial Sarcoma: An In Vitro and In Vivo Study Biomedicines 2025 13(3):534 PubMed ID: 40149512 DOI: 10.3390/biomedicines13030534

21887 Sasagawa S, Kumai J, Wakamatsu T, Yui Y. Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma. Cancer Innov 2024 3(2):e113 PubMed ID: 38946933 DOI: 10.1002/cai2.113

21911 Wang C, Wang M, Wang Y, Rej RK, Aguilar A, Xu T, Bai L, Tošović J, McEachern D, Li Q, Sarkari F, Wen B, Sun D, Wang S. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. J Med Chem 2024 PubMed ID: 39132814 DOI: 10.1021/acs.jmedchem.4c00971

22135 Li P, Zhai Z, Fan Y, Li W, Ke M, Li X, Gao H, Fu Y, Ma Z, Zhang W, Yi H, Ming J, Qin Y, Wang B, Kuang J, Pei D. Condensate remodeling reorganizes innate SS18 in synovial sarcomagenesis. Oncogenesis 2024 13(1):38 PubMed ID: 39468035 DOI: 10.1038/s41389-024-00539-w

22243 Sasaki M, Kato D, Yoshida H, Shimizu T, Ogiwara H. Efficacy of CBP/p300 Dual Inhibitors against De-repression of KREMEN2 in cBAF-Deficient Cancers Cancer Res Commun 2024 2024 Dec 3 PubMed ID: 39625239 DOI: 10.1158/2767-9764.CRC-24-0484

19674 Revia S, Budzinska MA, Bogatyrova O, Neumann F, Zimmermann A, Amendt C, Albers J. DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models Cancers (Basel) 2023 16(1):189 PubMed ID: 38201616 DOI: 10.3390/cancers16010189

19686 Takeuchi M, Nishisho T, Toki S, Kawaguchi S, Tamaki S, Oya T, Uto Y, Katagiri T, Sairyo K. Blue light induces apoptosis and autophagy by promoting ROS-mediated mitochondr Cancer Med 2023 12(8):9668-9683 PubMed ID: 36722116 DOI: 10.1002/cam4.5664

21280 Ban Y, Hoshi M, Oebisu N, Orita K, Iwai T, Yao H, Nakamura H. Anti-Tumor Effect and Neurotoxicity of Ethanol Adjuvant Therapy after Surgery of a Soft Tissue Sarcoma. Curr Oncol 2023 30(6):5251-5265 PubMed ID: 37366882 DOI: 10.3390/curroncol30060399

22619 Landuzzi L, Ruzzi F, Lollini PL, Scotlandi K. Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research Cancers (Basel) 2023 15(3):588 PubMed ID: 36765545 DOI: 10.3390/cancers15030588

17573 Raquib AR, Hofvander J, Ta M, Nielsen TO. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma Appl Immunohistochem Mol Morphol 2022 30(8):531-539 PubMed ID: 35880992 DOI: 10.1097/PAI.0000000000001049

20170 Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C. lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma. Oncol Lett 2021 21(6):455 PubMed ID: 33907565 DOI: 10.3892/ol.2021.12716

14894 Jerby-Arnon L, Neftel C, Shore ME, Weisman HR, Mathewson ND, McBride MJ, Haas B, Izar B, Volorio A, Boulay G, Cironi L, Richman AR, Broye LC, Gurski JM, Luo CC, Mylvaganam R, Nguyen L, Mei S, Melms JC, Georgescu C, Cohen O, Buendia-Buendia JE, Segerstolpe A, Sud M, Cuoco MS, Labes D, Gritsch S, Zollinger DR, Ortogero N, Beechem JM, Petur Nielsen G, Chebib I, Nguyen-Ngoc T, Montemurro M, Cote GM, Choy E, Letovanec I, Cherix S, Wagle N, Sorger PK, Haynes AB, Mullen JT, Stamenkovic I, Rivera MN, Kadoch C, Wucherpfennig KW, Rozenblatt-Rosen O, Suvà ML, Riggi N, Regev A. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma Nat Med 2021 ;27(2):289-300 PubMed ID: 33495604 DOI: 10.1038/s41591-020-01212-6

15529 Boulay G, Cironi L, Garcia SP, Rengarajan S, Xing YH, Lee L, Awad ME, Naigles B, Iyer S, Broye LC, Keskin T, Cauderay A, Fusco C, Letovanec I, Chebib I, Nielsen PG, Tercier S, Cherix S, Nguyen-Ngoc T, Cote G, Choy E, Provero P, Suvà ML, Rivera MN, Stamenkovic I, Riggi N. The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies Life Sci Alliance 2021 4(2):e202000808 PubMed ID: 33361335 DOI: 10.26508/lsa.202000808

16177 Fairchild CK Jr, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA. Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA Cancers (Basel) 2021 13(10):2310 PubMed ID: 34065859 DOI: 10.3390/cancers13102310

13035 Sekita T, Yamada T, Kobayashi E, Yoshida A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Matsumoto M, Nakamura M, Nakayama R, Masuda M. Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma. Cancers (Basel) 2020 PubMed ID: 32429395 DOI: 10.3390/cancers12051258

14524 Abe K, Yamamoto N, Domoto T, Bolidong D, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Inatani H, Aoki Y, Higuchi T, Taniguchi Y, Yonezawa H, Araki Y, Aiba H, Minamoto T, Tsuchiya H. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma Cancer Sci 2020 111(2):429-440 PubMed ID: 31808966 DOI: 10.1111/cas.14271

14832 Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y. Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines Arch Virol 2020 165(1):207-214 PubMed ID: 31776677 DOI: 10.1007/s00705-019-04474-9

14603 Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM, Pan J, Remillard DI, Lareau CA, Zullow HJ, Fortoul N, Gray NS, Bradner JE, Chan HM, Kadoch C. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation Nat Cell Biol 2018 20(12):1410-1420 PubMed ID: 30397315 DOI: 10.1038/s41556-018-0221-1

10309 Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma. BMC Cancer 2017 17:334 PubMed ID: 28511645 DOI: 10.1186/s12885-017-3324-3

14617 Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ. ATR Is a Therapeutic Target in Synovial Sarcoma Cancer Res 2017 77(24):7014-7026 PubMed ID: 29038346 DOI: 10.1158/0008-5472.CAN-17-2056

18190 Cironi L, Petricevic T, Fernandes Vieira V, Provero P, Fusco C, Cornaz S, Fregni G, Letovanec I, Aguet M, Stamenkovic I. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma Sci Rep 2016 6:22113 PubMed ID: 26905812 DOI: 10.1038/srep22113

9547 Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N. Trabectedin is a promising antitumour agent for synovial sarcoma. J Chemother 2016 28:417-24 PubMed ID: 27077926 DOI: 10.1080/1120009X.2015.1133013

9557 Sakurai T, Yoshiga D, Ariyoshi W, Okinaga T, Kiyomiya H, Furuta J, Yoshioka I, Tominaga K, Nishihara T. Essential role of mitogen-activated protein kinases in IL-17A-induced MMP-3 expression in human synovial sarcoma cells. BMC Res Notes 2016 9:68 PubMed ID: 26850593 DOI: 10.1186/s13104-016-1892-y

9653 Kawano S, Asano M, Adachi Y, Matsui J. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Res. 2016 36:1553-61 PubMed ID: 27069131

9751 Kawano S, Grassian AR, Tsuda M, Knutson SK, Warholic NM, Kuznetsov G, Xu S, Xiao Y, Pollock RM, Smith JS, Kuntz KK, Ribich S, Minoshima Y, Matsui J, Copeland RA, Tanaka S, Keilhack H. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS ONE 2016 11:e0158888 PubMed ID: 27391784 DOI: 10.1371/journal.pone.0158888

10919 Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma Integr Mol Med 2016 3: 755-760 DOI: 10.15761/IMM.1000239

14025 Imura Y, Nakai T, Yamada S, Outani H, Takenaka S, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma Cancer Sci 2016 107(12):1867-1876 PubMed ID: 27779808 DOI: 10.1111/cas.13092

7359 Mikami T, Kurose A, Javed F, Takeda Y. Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review. J. Oral Maxillofac. Surg. 2015 73:1505-15 PubMed ID: 25959879 DOI: 10.1016/j.joms.2015.02.010

13716 Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features Int J Biochem Cell Biol 2014 53:505-13 PubMed ID: 24842110 DOI: 10.1016/j.biocel.2014.05.006

18251 Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling Int J Oncol 2011 39(1):73-89 PubMed ID: 21537839 DOI: 10.3892/ijo.2011.1020

8002 Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H. Identification of altered MicroRNA expression patterns in synovial sarcoma. Genes Chromosomes Cancer 2011 50:137-45 PubMed ID: 21213367 DOI: 10.1002/gcc.20837